Abstract：Drug resistance is one of the culprits leading to the failure of drug treatment in hepatocellular carcinoma patients. In recent years, many studies have confirmed the pharmacokinetic mechanism, especially the important role of drug efflux pumps and drug metabolic enzymes in hepatocellular carcinoma(HCC) resistance. Drug efflux caused by drug efflux pumps, such as ATP-binding cassette(ABC) transporters, reduces the concentration of drugs in tumor cells and greatly reduces the efficacy of drugs and drug metabolism enzymes(DMEs)cause changes or even loss of drug activity by two-phase metabolic reactions, which is also pharmacokinetic-related resistance. This article mainly reviews recent studies on drug efflux pumps and drug metabolism enzymes involved in HCC drug resistance and focus on the analysis of ABC transporters and drug metabolism enzymes. This review is intended to explain the relevant mechanisms of HCC drug resistance from the perspective of pharmacokinetics and provide ideas for solving drug resistance of HCC and prolonging the survival of patients.
吴亚菲, 张吉刚, 李琴. 肝细胞癌药物治疗耐药的药动学机制研究进展[J]. 中国药学杂志, 2020, 55(19): 1578-1584.
WU Ya-fei, ZHANG Ji-gang, LI Qin. Progress in the Pharmacokinetic Mechanism of Drug Resistance in Hepatocellular Carcinoma. Chinese Pharmaceutical Journal, 2020, 55(19): 1578-1584.
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1):7-30.
[2]
FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma. Lancet, 2018, 391(10127):1301-1314.
[3]
VILLANUEVA A. Hepatocellular carcinoma. N Engl J Med, 2019, 380(15):1450-1462.
[4]
CHOI K J, BAIK I H, YE S K, et al. Molecular targeted therapy for hepatocellular carcinoma: present status and future directions. Biol Pharm Bull, 2015, 38(7):986-991.
[5]
YAMAMOTO S, KONDO S. Oral chemotherapy for the treatment of hepatocellular carcinoma. Expert Opin Pharmacother, 2018, 19(9):993-1001.
[6]
CUCCHETTI A, PISCAGLIA F, PINNA A D, et al. Efficacy and safety of systemic therapies for advanced hepatocellular carcinoma: an network Meta-analysis of phase Ⅲ trials. Liver Cancer, 2017, 6(4):337-348.
[7]
BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 389(10064):56-66.
[8]
VERMA H, SINGH BAHIA M, CHOUDHARY S, et al. Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it. Drug Metab Rev, 2019, 51(2):196-223.
[9]
TRUNZER K, PAVLICK A C, SCHUCHTER L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol, 2013, 31(14):1767-1774.
[10]
HOLOHAN C, VAN SCHAEYBROECK S, LONGLEY D B, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer, 2013, 13(10):714-726.
[11]
JOVE M, SPENCER J, CLENCH M, et al. Precision pharmacology: mass spectrometry imaging and pharmacokinetic drug resistance. Crit Rev Oncol Hematol, 2019, 141:153-162.
[12]
ROBEY R W, PLUCHINO K M, HALL M D, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer, 2018, 18(7):452-464.
[13]
WANG R, ZHANG T, YANG Z, et al. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med, 2018, 22(9):4068-4075.
[14]
WU D D, LI X S, MENG X N, et al. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumour Biol, 2016, 37(8):10499-10506.
[15]
ZHAO Y, QI X, CHEN J, et al. The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Lett, 2017, 408:102-111.
[16]
SU Z, LIU G, FANG T, et al. Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy. Am J Transl Res, 2016, 8(6):2790-2802.
[17]
LI W, ZHANG H, ASSARAF Y G, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat, 2016, 27:14-29.
[18]
CEBALLOS M P, RIGALLI J P, CERÉ L I, et al. ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem, 2019, 26(7):1224-1250.
[19]
DONG J, QIN Z, ZHANG W D, et al. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update. Drug Resist Updat, 2020, 49:100681
[20]
BOREL F, HAN R, VISSER A, et al. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology (Baltimore, Md.), 2012, 55(3):821-832.
[21]
COLOMBO F, TROMBETTA E, CETRANGOLO P, et al. Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells. PLoS One, 2014, 9(12):e114787-e114787.
[22]
RIGALLI J P, CIRIACI N, ARIAS A, et al. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One, 2015, 10(3):e0119502-e0119502.
[23]
LIANG Y, ZHENG T, SONG R, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology (Baltimore, Md.), 2013, 57(5):1847-1857.
[24]
JETTER A, KULLAK-UBLICK G A. Drugs and hepatic transporters: a review. Pharmacol Res, 2020,154:104234.
[25]
KEPPLER D. Multidrug resistance proteins (MRPs, ABCCs):importance for pathophysiology and drug therapy. Handb Exp Pharmacol, 2011,(201):299-323.
[26]
JOHNSON Z L, CHEN J. Structural basis of substrate recognition by the multidrug resistance protein MRP1. Cell, 2017, 168(6):1075-1085.
[27]
FOUQUET G, DEBUYSSCHER V, OULED-HADDOU H, et al. Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget, 2016, 7(22):32493-32503.
[28]
KATAOKA J, SHIRAHA H, HORIGUCHI S, et al. Loss of runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma. Oncol Rep, 2016, 35(5):2576-2582.
[29]
LING S, LI J, SHAN Q, et al. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol, 2017, 11(6):682-695.
[30]
LIN S, HOFFMANN K, XIAO Z, et al. MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int, 2013, 13(1):3-3.
[31]
COLE S P C. Targeting multidrug resistance protein 1 (MRP1, ABCC1):past, present, and future. Annu Rev Pharmacol Toxicol, 2014, 54:95-117.
[32]
TANDIA M, MHIRI A, PAULE B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2):monocentric study. Cancer Chemother Pharmacol, 2017, 79(4):759-766.
[33]
CHEN Y L, CHEN P M, LIN P Y, et al. ABCG2 overexpression confers poor outcomes in hepatocellular carcinoma of elderly patients. Anticancer Res, 2016, 36(6):2983-2988.
[34]
SUKOWATI C H, ROSSO N, PASCUT D, et al. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol, 2012, 12:160.
[35]
SUN Z, ZHAO Z, LI G, et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori, 2010, 96(1):90-96.
[36]
KONG J, QIU Y, LI Y, et al. TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis. Biopharm Drug Dispos, 2019, 40(2):70-80.
[37]
BHAGYARAJ E, AHUJA N, KUMAR S, et al. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. Cell Cycle, 2019, 18(24):3589-3602.
[38]
LI H, ZHOU S, LI T, et al. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference. Hepatogastroenterology, 2012, 59(119):2238-2242.
[39]
TAKAHASHI K, YAN I K, WOOD J, et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res, 2014, 12(10):1377-1387.
[40]
SOUSA D, LIMA R T, VASCONCELOS M H. Intercellular transfer of cancer drug resistance traits by extracellular vesicles. Trends Mol Med, 2015, 21(10):595-608.
[41]
YANG X R, XU Y, YU B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 2010, 59(7):953-962.
[42]
SHI G M, XU Y, FAN J, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol, 2008, 134(11):1155-1163.
[43]
FUNG S W, CHEUNG P F, YIP C W, et al. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Lett, 2019, 457:98-109.
[44]
NAMISAKI T, SCHAEFFELER E, FUKUI H, et al. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab Dispos, 2014, 42(12):2033-2040.
[45]
ROBEY R W, PLUCHINO K M, HALL M D, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer, 2018, 18(7):452-464.
[46]
LI R, XU T, WANG H, et al. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochem Biophys Res Commun, 2019, 519(2):358-365.
[47]
KIMCHI-SARFATY C, OH J M, KIM I W, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 2007, 315(5811):525-528.
[48]
SU Z, LIU G, FANG T, et al. Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy. Am J Transl Res, 2016, 8(6):2790-2802.
[49]
ZHAO J, YU B Y, WANG D Y, et al. Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma. World J Gastroenterol, 2010, 16(48):6104-6110.
[50]
TANDIA M, MHIRI A, PAULE B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2):monocentric study. Cancer Chemother Pharmacol, 2017, 79(4):759-766.
[51]
DI GIACOMO S, BRIZ O, MONTE M J, et al. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch Toxicol, 2019, 93(3):623-634.
[52]
FENG S, LI A, ZHENG Y C, et al. Role of drug-metabolizing enzymes in cancer and cancer therapy. Curr Drug Metab, 2020, 21(1):67-76.
[53]
UNDERHILL G H, KHETANI S R. Advances in engineered human liver platforms for drug metabolism studies. Drug Metab Dispos, 2018, 46(11):1626-1637.
[54]
LI Y, STEPPI A, ZHOU Y, et al. Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. Sci Rep, 2017, 7(1):4747-4747.
[55]
KULMA I, BOONPRASERT K, NA-BANGCHANG K. Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review. Cancer Chemother Pharmacol, 2019, 84(5):959-975.
[56]
GUO X G, WANG Z H, DONG W, et al. Specific CYP450 genotypes in the Chinese population affect sorafenib toxicity in HBV/HCV-associated hepatocellular carcinoma patients. Biomed Environ Sci, 2018, 31(8):586-595.
[57]
UL-ISLAM S, AHMED M B, SHEHZAD A, et al. Failure of chemotherapy in hepatocellular carcinoma due to impaired and dysregulated primary liver drug metabolizing enzymes and drug transport proteins: what to do?. Curr Drug Metab, 2018, 19(10):819-829.
[58]
CHEN C H, FERREIRA J C B, GROSS E R, et al. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev, 2014, 94(1):1-34.
[59]
AHMED LASKAR A, YOUNUS H. Aldehyde toxicity and metabolism: the role of aldehyde dehydrogenases in detoxification, drug resistance and carcinogenesis. Drug Metab Rev, 2019, 51(1):42-64.
[60]
TOMITA H, TANAKA K, TANAKA T, et al. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget, 2016, 7(10):11018-11032.
[61]
CALDERARO J, NAULT J C, BIOULAC-SAGE P, et al. ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/β-catenin pathway. Virchows Arch, 2014, 464(1):53-60.
[62]
LAI S C, SU Y T, CHI C C, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res, 2019, 38(1):474-474.
[63]
WILSON G S, HU Z, DUAN W, et al. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. Stem Cells Dev, 2013, 22(19):2655-2664.
[64]
NIO K, YAMASHITA T, KANEKO S. The evolving concept of liver cancer stem cells. Molecular Cancer, 2017, 16(1):4.
[65]
CASTELLI G, PELOSI E, TESTA U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel), 2017, 9(9):127.
[66]
TOLEDO-GUZMÁN M E, HERNÁNDEZ M I, GÓMEZ-GALLEGOSÁ A, et al. ALDH as a stem cell marker in solid tumors. Curr Stem Cell Res Ther, 2019, 14(5):375-388.
[67]
YAN T, GAO S, PENG X, et al. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method. Pharm Res, 2015, 32(3):1141-1157.
[68]
LU L, ZHOU J, SHI J, et al. Drug-metabolizing activity, protein and gene expression of UDP-glucuronosyltransferases are significantly altered in hepatocellular carcinoma patients. PLoS One, 2015, 10(5):e0127524-e0127524.
[69]
BRANDON E F A, SPARIDANS R W, MEIJERMAN I, et al. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Invest New Drugs, 2004, 22(3):241-251.
[70]
EVANCHIK M J, ALLEN D, YOBURN J C, et al. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin, formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos, 2009, 37(3):594-601.
[71]
GE Y, CHEN S, MU W, et al. Epigenetic regulation of UDP-glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. Cancer Lett, 2019, 454:14-25.
[72]
GOLDSTEIN I, RIVLIN N, SHOSHANA O Y, et al. Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis, 2013, 34(1):190-198.
[73]
MEECH R, HU D G, MCKINNON R A, et al. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev, 2019, 99(2):1153-1222.
[74]
MAZERSKA Z, MRÓZ A, PAWŁOWSKA M, et al. The role of glucuronidation in drug resistance. Pharmacol Ther, 2016, 159:35-55.
[75]
HU D G, MACKENZIE P I, MCKINNON R A, et al. Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. Drug Metab Rev, 2016, 48(1):47-69.
[76]
YAN T, LU L, XIE C, et al. Severely impaired and dysregulated cytochrome P450 expression and activities in hepatocellular carcinoma: implications for personalized treatment in patients. Mol Cancer Ther, 2015, 14(12):2874-2886.
[77]
ZHOU J, WEN Q, LI S F, et al. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget, 2016, 7(31):50612-50623.
[78]
KAMDEM L K, FLOCKHART D A, DESTA Z, In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos, 2011, 39(1):98-105.
[79]
CHEN H, SHEN Z Y, XU W, et al. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol, 2014, 20(26):8681-8690.
[80]
TIBBS Z E, ROHN-GLOWACKI K J, CRITTENDEN F, et al. Structural plasticity in the human cytosolic sulfotransferase dimer and its role in substrate selectivity and catalysis. Drug Metab Pharmacokinet, 2015, 30(1):3-20.
[81]
WANG X R, QU Z Q, LI X D, et al. Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection. Cancer Sci, 2010, 101(2):412-415.
[82]
ZHOU H, LI Y, SONG X, et al. CHST11/13 regulate the metastasis and chemosensitivity of human hepatocellular carcinoma cells via mitogen-activated protein kinase pathway. Dig Dis Sci, 2016, 61(7):1972-1985.
[83]
PLJESA-ERCEGOVAC M, SAVIC-RADOJEVIC A, MATIC M, et al. Glutathione transferases: potential targets to overcome chemoresistance in solid tumors. Int J Mol Sci, 2018, 19(12):3785.
[84]
MISHRA M, JAYAL P, KARANDE A A, et al. Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach. FEBS J, 2018, 285(21):3977-3992.
[85]
WEI L, LEE D, LAW C T, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun, 2019, 10(1):4681.
[86]
ZHU W P, LIU Z Y, ZHAO Y M, et al. Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma. Cell Death Dis, 2018, 9(2):69.
[87]
OKANO Y, KURAMOCHI H, NAKAJIMA G, et al. Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1. Oncol Lett, 2017, 14(1):930-936.
[88]
WANG C, FANG P F, CAI H L. Research progress of ABC membrane transporters and their regulation in tumor drug resistance and new mechanism of detoxification. Chin Pharm J(中国药学杂志), 2017, 52(22):1961-1965.
[89]
ZHENG J Q, WANG Q, YANG X, et al. Research progress in toxic effects of antitumor drugs mediated by drug metabolism enzymes and isoforms. Chin Pharm J(中国药学杂志), 2017, 52(13):1115-1119.
2020, Vol. 55 
